Want to see TCMD full AI Analyst Report?
TCMD Stock Chart & Stats
$25.73
$0.01(0.06%)
At close: 4:00 PM EST
$25.73
$0.01(0.06%)
Day’s Range― - ―
52-Week Range$9.42 - $37.77
Previous CloseN/A
Volume58.88K
Average Volume (3M)239.20K
Market Cap
$648.27M
Enterprise Value$529.70
Total Cash (Recent Filing)$74.99M
Total Debt (Recent Filing)$15.17M
Price to Earnings (P/E)31.9
Beta0.65
Next Earnings
Aug 10, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.90
Shares Outstanding22,556,260
10 Day Avg. Volume200,389
30 Day Avg. Volume239,197
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)3.03
Price to Sales (P/S)2.01
P/FCF Ratio16.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$39.50Price Target Upside53.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.14
Revenue Forecast (FY)$364.81M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a strengthening balance sheet provide durable financial flexibility. With minimal debt relative to equity, the company can fund working capital, M&A, product investments, and share repurchases without heavy refinancing risk, insulating operations from reimbursement timing volatility.
Strong Cash GenerationConsistent high-quality cash generation and healthy cash conversion support sustainable investment in R&D, sales infrastructure, and M&A integration. Robust FCF versus net income indicates earnings quality and provides a buffer against cyclical payer delays or temporary revenue cadence shifts.
Product And Federal Market ExpansionSecuring exclusive federal distribution for a complementary ambulatory compression device broadens the addressable market and leverages established billing and clinical support. This durable channel expansion can diversify revenue, deepen institutional relationships, and accelerate commercialization beyond consumer channels.
Bears Say
Medicare Prior-authorization UncertaintyA structural change in Medicare prior-authorization processes creates persistent execution and timing risk. Variable MAC outcomes can delay patient approvals, compress near-term cadence, and complicate forecasting and collections, materially affecting revenue recognition and sales productivity for months ahead.
Higher Operating ExpensesSustained increases in sales, R&D and G&A spending elevate the operating cost base. If revenue growth moderates or cadence timing shifts persist, higher recurring expenses will pressure operating leverage and require sustained revenue acceleration to restore prior margin levels.
Lower-margin Acquisition MixAcquired revenue components with lower margins, including grant and service receipts, can dilute consolidated gross and EBITDA margins. Until integration yields cross-sell and efficiency gains, the changed revenue mix may structurally limit margin expansion despite higher top-line figures.
Tactile Systems Technology News
TCMD FAQ
What was Tactile Systems Technology’s price range in the past 12 months?
Tactile Systems Technology lowest stock price was $9.41 and its highest was $37.77 in the past 12 months.
What is Tactile Systems Technology’s market cap?
Tactile Systems Technology’s market cap is $648.27M.
When is Tactile Systems Technology’s upcoming earnings report date?
Tactile Systems Technology’s upcoming earnings report date is Aug 10, 2026 which is in 22 days.
How were Tactile Systems Technology’s earnings last quarter?
Tactile Systems Technology released its earnings results on May 04, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.04.
Is Tactile Systems Technology overvalued?
According to Wall Street analysts Tactile Systems Technology’s price is currently Undervalued.
Does Tactile Systems Technology pay dividends?
Tactile Systems Technology does not currently pay dividends.
What is Tactile Systems Technology’s EPS estimate?
Tactile Systems Technology’s EPS estimate is 0.14.
How many shares outstanding does Tactile Systems Technology have?
Tactile Systems Technology has 22,556,260 shares outstanding.
What happened to Tactile Systems Technology’s price movement after its last earnings report?
Tactile Systems Technology reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went up 7.222%.
Which hedge fund is a major shareholder of Tactile Systems Technology?
Currently, no hedge funds are holding shares in TCMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tactile Systems Technology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.50 (53.52% Upside)
$39.50 (53.52% Upside)
Blogger Sentiment
Bullish
TCMD Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 176.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $113.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
187.11%
12-Months-Change
Fundamentals
Return on Equity
9.70%
Trailing 12-Months
Asset Growth
-2.90%
Trailing 12-Months
Company Description
Tactile Systems Technology
Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.
TCMD Stock 12 Month Forecast
Average Price Target
$39.50
▲(53.52% Upside)
Technical Analysis
Sanuwave Health
―
Viemed Healthcare
―
Outset Medical
―
TriSalus Life Sciences
―
Ceribell, Inc.
―
Ownership Overview
3.57% Insiders
20.55% Mutual Funds
0.49% Other Institutional Investors
56.60% Public Companies and
Individual Investors